BioCardia Release: Phase 2 TAC-HFT Trial Shows Excellent Safety Profile, Suggests Efficacy, For Transendocardial Delivery Of Two Types Of Autologous Cells For Ischemic Heart Failure

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DALLAS--(BUSINESS WIRE)--BioCardia®, Inc., a leader in cardiovascular regenerative medicine, today announced positive 12-month results for the randomized Transendocardial Autologous Cells (MSC or BMC) in Ischemic Heart Failure Trial (TAC-HFT). The Phase II trial demonstrated the safety of transendocardial stem cell injection (TESI) of autologous culture-expanded mesenchymal cells (MSCs) and autologous minimally-processed whole bone marrow mononuclear cells (BMCs) delivered by the company’s Helical Infusion Catheter System™ in the treatment of chronic ischemic cardiomyopathy (ICM). The trial results were concurrently reported today in the Journal of the American Medical Association (JAMA) and presented by lead investigator Joshua Hare, MD from the University of Miami as a late-breaking presentation at the American Heart Association’s 2013 Scientific Sessions. The JAMA article is located at:

Help employers find you! Check out all the jobs and post your resume.

Back to news